{"id":"NCT05896748","sponsor":"ViiV Healthcare","briefTitle":"Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study","officialTitle":"An Amendment to the FLAIR Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Maintenance of Virological Suppression and Patient Reported Outcomes for Participants Receiving Cabotegravir (CAB 200 mg/mL) and Rilpivirine (300 mg/mL) Long-Acting Injections Following Sub-cutaneous (SC) Administration in the Anterior Abdominal Wall SC Tissue Compared With Intramuscular (IM) Administration in the Gluteus Medius Muscle in Adult Participants Living With HIV-1 Infection in the FLAIR Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-11-08","primaryCompletion":"2023-09-14","completion":"2023-09-14","firstPosted":"2023-06-09","resultsPosted":"2024-11-26","lastUpdate":"2024-11-26"},"enrollment":94,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Type 1 (HIV-1)"],"interventions":[{"type":"DRUG","name":"Cabotegravir - Injectable Suspension (CAB LA)","otherNames":[]},{"type":"DRUG","name":"Rilpivirine - Injectable Suspension (RPV LA)","otherNames":[]}],"arms":[{"label":"Cabotegravir Long Acting (CAB LA) 400 Milligrams (mg) + Rilpivirine Long Acting (RPV) LA 600 mg","type":"EXPERIMENTAL"}],"summary":"This study will assess the pharmacokinetics, safety, tolerability, maintenance of virological suppression and patient reported outcomes for participants receiving CAB and RPV LA injections following SC administration in the anterior abdominal wall SC tissue compared with IM administration in the gluteus medius muscle in adult participants living with HIV-1 infection in the FLAIR study (NCT02938520).","primaryOutcome":{"measure":"Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA","timeFrame":"At screening Week-4; Day 1, Week 4, Week 8 for SC injections; and Week 12 for Return to IM gluteal injection","effectByArm":[{"arm":"CAB+RPV Screening Gluteal Injection","deltaMin":2.759,"sd":36.64},{"arm":"CAB+RPV First Sub-Cutaneous (SC) Injection","deltaMin":2.67,"sd":37.02},{"arm":"CAB+RPV Second SC Injection","deltaMin":2.607,"sd":39},{"arm":"CAB+RPV Last SC Injection","deltaMin":2.632,"sd":38.87},{"arm":"CAB+RPV Return to Intramuscular (IM) Gluteal Injection","deltaMin":2.797,"sd":36.18}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG000 vs OG004","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":38},"locations":{"siteCount":30,"countries":["United States","Canada","Japan","South Africa","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":94},"commonTop":["Injection site pain","Injection site nodule","Injection site erythema","Injection site swelling","Injection site induration"]}}